Globus Medical, Inc.

GMED · NYSE · Stock · Healthcare
$78.84
+3.32% today
Delayed price,

What Globus Medical does

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Key facts

Sector
Healthcare
Industry
Medical Devices
Market cap
$10.59B
P/E (ttm)
20.2
Forward P/E
14.6
Dividend yield
0.00%
Beta
0.96
Profit margin
17.0%
Employees
6,000
Headquarters
Audubon, PA, United States
Exchange
NYSE

Performance

1 Month
+6.4%
3 Months
+2.4%
6 Months
-17.2%
1 Year
+32.3%
5 Years
+25.9%
$58.3252-week range$101.40
Biggest setback — last 12 months
-22.4%
23 Feb 2026 → 14 Sept 2026
Fell from $95.46 to $74.08 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+60.2%
13 Oct 2025 → 23 Feb 2026
Ran from $59.58 to $95.46 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Below long-term trend
Price sits below its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$70.71 (-10.3%)$78.84$87.91 (+11.5%)
3 Months$65.29 (-17.2%)$78.84$95.21 (+20.8%)
6 Months$60.38 (-23.4%)$78.84$102.94 (+30.6%)
12 Months$54.06 (-31.4%)$78.84$114.97 (+45.8%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 37.7%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent insider activity

Sold 60,000 shares at $74.58 — TOBIN JAMES R, Director · 2026-09-16
Sold 50,000 shares at $87.04 — ZARRILLI STEPHEN T, Director · 2026-08-19
Sold 2,500 shares — Davidar David D, Director · 2026-07-28
Sold 50,000 shares at $80.76 — Davidar David D, Director · 2026-06-09
Acquired 25,000 shares at $26.27 — RHOADS ANN D, Director · 2026-06-08
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.